3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
22
Lymphoma, Follicular
14
Lymphoma, B-Cell, Marginal Zone
11
Lymphoma
11
Lymphoma, Mantle-Cell
10
Lymphoma, Non-Hodgkin
7
Lymphoma, Large B-Cell, Diffuse
6
Neoplasms
4
Lymphoma, B-Cell
4
Recurrence
3
Burkitt Lymphoma
3
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm, Residual
1
Melanoma
1
Mature B-cell Malignancies
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, Hairy Cell
1
Leukemia, B-Cell
1
Leukemia
1
Heart Failure
1
Extensive Stage Small Cell Lung Cancer
1
Dendritic Cell Sarcoma, Interdigitating
1
Cytokine Release Syndrome
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Rituximab
7
zanubrutinib
6
venetoclax
4
ibrutinib
3
Dexamethasone
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Biopsy
2
Bendamustine Hydrochloride
2
pirtobrutinib
1
obinutuzumab
1
Positron-Emission Tomography
1
Lenalidomide
1
Exercise
1
Diet
1
CT-P10
1
Bortezomib
1
ARQ531
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Waldenstrom Macroglobulinemia
×
obinutuzumab
×
Clear all
NCT05326308
2025-09-23
ARIADNE
iOMEDICO AG
Recruiting
705 enrolled